Monitoring T cell alloreactivity

Anita Mehrotra, Jeremy Leventhal, Carolina Purroy, Paolo Cravedi

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Currently, immunosuppressive therapy in kidney transplant recipients is center-specific, protocol-driven, and adjusted according to functional or histological evaluation of the allograft and/or signs of drug toxicity or infection. As a result, a large fraction of patients receive too much or too little immunosuppression, exposing them to higher rates of infection, malignancy and drug toxicity, or increased risk of acute and chronic graft injury from rejection, respectively. The individualization of immunosuppression requires the development of assays able to reliably quantify and/or predict the magnitude of the recipient's immune response toward the allograft. As alloreactive T cells are central mediators of allograft rejection, monitoring T cell alloreactivity has become a priority for the transplant community. Among available assays, flow cytometry based phenotyping, T cell proliferation, T cell cytokine secretion, and ATP release (ImmuKnow), have been the most thoroughly tested. While numerous cross-sectional studies have found associations between the results of these assays and the presence of clinically relevant post-transplantation outcomes, data from prospective studies are still scanty, thereby preventing widespread implementation in the clinic. Future studies are required to test the hypothesis that tailoring immunosuppression on the basis of results offered by these biomarkers leads to better outcomes than current standard clinical practice.

Original languageEnglish
Pages (from-to)53-59
Number of pages7
JournalTransplantation Reviews
Issue number2
StatePublished - 1 Apr 2015


Dive into the research topics of 'Monitoring T cell alloreactivity'. Together they form a unique fingerprint.

Cite this